| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/21/2008 | US20080200550 Inhibition of Hiv-1 Replication by Disruption of the Processing of the Viral Capsid-Spacer Peptide 1 Protein |
| 08/21/2008 | US20080200549 Analgesics; pain management |
| 08/21/2008 | US20080200548 N-Acetylcysteine Amide (Nac Amide) for Treatment of Oxidative Stress Associated with Infertility |
| 08/21/2008 | US20080200547 Highly Purified Ethyl EPA and Other EPA Derivatives |
| 08/21/2008 | US20080200545 Peeling process with surfactants |
| 08/21/2008 | US20080200543 side effects reduction; nontoxic; AIDS, a sepsis, anticancer agent; 1-oleoyl-2-2palmitoyl-3-acetylglycerol(R1/R2=9-octadecenoyl/hexadecanoyl; immune enhancing agent |
| 08/21/2008 | US20080200541 Central nervous system disorders; schizophrenia; serotonine receptor antagonist; side effect reduction |
| 08/21/2008 | US20080200540 Antiparasitic agents |
| 08/21/2008 | US20080200539 Using mixture of triacetin, tolnaftate, and synthetic vitamin A; therapy for skin and nail infections; reducing moisture of affected tissue |
| 08/21/2008 | US20080200538 Inhibition of Monocyte Survival, Differentiation, or Proliferation |
| 08/21/2008 | US20080200537 Administering extract from soy plants grown under stressed conditions; inhibiting selective estrogen receptor modulator induced uterotrophic effects |
| 08/21/2008 | US20080200536 Pharmaceutical Formulation with High Stability and Dissolution and Manufacturing Process |
| 08/21/2008 | US20080200535 Amine Compounds |
| 08/21/2008 | US20080200534 Slimming body milk; reducing cellulite and/or orange peel appearance |
| 08/21/2008 | US20080200533 Creating modified complex molecules having reduced toxicity and enhanced bioavailability; such as reaction product of atorvastatin and 2,6-diaminohexanoic acid; increasing solubility; reducing dosage levels |
| 08/21/2008 | US20080200532 Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them |
| 08/21/2008 | US20080200531 CDKI pathway inhibitors as inhibitors of tumor cell growth |
| 08/21/2008 | US20080200530 compound is a selective 5-HT2A inverse agonist or inhibits JC virus infection of human glial cells in patients with carcinomas, lymphoproliferative disorder, HIV, AIDS, immunosupressive therapy; 1-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(4-fluoro-phenyl)-urea; pyrazole, urea or thiourea |
| 08/21/2008 | US20080200529 Novel 2-Amino Benzimidazole Derivatives and Their Use As Modulators Of Small-Conductance Calcium-Activated Potassium Channels |
| 08/21/2008 | US20080200528 Derivatives of a 1-Phenyltriazole |
| 08/21/2008 | US20080200527 obesity, metabolic syndrome, Type II diabetes, cardiovascular disease, osteoarthritis, cancers; mental disorders; sexual and/or reproductive dysfunctions, epilepsy; 5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-methyl-1H-pyrazole-3-carboxylic acid [3-(1H-tetrazol-5-yl)-propyl]-amide |
| 08/21/2008 | US20080200526 N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine, 4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine; allergic rhinitis, asthma, allergic conjunctivitis, allergic dermatitis, atopic dermatitis, contact dermatitis and urticaria |
| 08/21/2008 | US20080200524 Treating pain, inflammation and traumatic injury; using 2-pyridinyl-phenyl-4-amido-p-sulfono or sulfonamidobenzene derivatives |
| 08/21/2008 | US20080200523 Derivatives of squaric acid with anti-proliferative activity |
| 08/21/2008 | US20080200521 Novel hydroxamic acid containing amino acid derivatives |
| 08/21/2008 | US20080200520 Iron Modulators |
| 08/21/2008 | US20080200519 5-Amino-1-(4-fluorophenyl)-N-[6-fluoro-1,2,3,4-tetrahydro-2-hydroxy-5-methoxy-4,4-dimethyl-2-(trifluoromethyl)naphthalene-1-yl]-1H-pyrazole-4-carboxamide; selectivity to glucocorticoid receptor; fewer side effect; inhibit secretion of cytokine IL-8 into monocyte cell line THP-1 triggered by lipopolysacch |
| 08/21/2008 | US20080200518 insecticides, acaricides; crops, foods and goods; a urea, a thiourea or a guanidine; ring is imidazole or 1,2,4-triazole or tetrazole; 4-{4-[4-(3,3-Dichloroprop-2-enyloxy)-2,6-dichlorophenoxy]butyl}-1-[4-(trifluoromethyl)phenyl]-1,2,4-triazolin-5-one; a 1,2,3,4-tetrazolin-5-one |
| 08/21/2008 | US20080200517 Racemic 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl)-1H-benzimidazole (ilaprazole) solvates having distinctive x-ray powder diffraction patterns and DSC thermograms; inhibiting gastric acid secretion; gastrointestinal inflammatory disorders; solubility, stability |
| 08/21/2008 | US20080200516 Solid state forms of racemic ilaprazole |
| 08/21/2008 | US20080200515 Solid state forms of enantiopure ilaprazole |
| 08/21/2008 | US20080200514 Neurodegeneration, cancer, rheumatoid disordes, kidney diseases, diabetes; such as dabigatran etexilate |
| 08/21/2008 | US20080200513 Pyridine N-Oxides As Antiviral Agents |
| 08/21/2008 | US20080200512 Hepatitis C virus polymerase inhibitors |
| 08/21/2008 | US20080200511 Novel Compounds and Methods of Using the Same |
| 08/21/2008 | US20080200510 Combination of Organic Compounds |
| 08/21/2008 | US20080200509 Utilizing such as 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide against cancer growth |
| 08/21/2008 | US20080200508 Controlled extended release of serotonin receptor anatagonist; alleviating sleep apnea; kits |
| 08/21/2008 | US20080200507 Water and organic solvent free crystal lattice; hydrophobic, water soluble; endometriosis and/or uterine leiomyoma; commercial scale; X ray diffraction pattern having peaks at 13.0, 13.6, 18.6, 19.0, 21.0 and 22.3 degrees |
| 08/21/2008 | US20080200506 Oral Preparation of Dyclonine Hydrochloride |
| 08/21/2008 | US20080200505 Piperidines for the Treatment of Chemokine Mediated Diseases |
| 08/21/2008 | US20080200504 non-peptide NK-3 receptor ligands; anxiety, depression, schizophrenia, obesity; 2-Phenyl-quinoline-4-carboxylic acid (1-pyridin-4-yl-propyl) amide; reacting the 2-phenyl-quinolinyl-4-carbonyl chloride with a pyridylalkylamine to form the amide |
| 08/21/2008 | US20080200503 Bioavailable formulations with ritonavir; potency, decreased cytotoxicity, improved pharmacokinetics; N-[18-[2-(4-isopropylthiazol-2-yl)-7-methoxyquinolin-4-yl-oxy]-2,15-dioxo- -3,14,16-triazatricyclo[14.3.0.0.sup.4,6]nonadec-7-ene-4-carbonyl]-(cyclopropyl)sulfonamide |
| 08/21/2008 | US20080200502 Methods of lowering lipid levels in a mammal |
| 08/21/2008 | US20080200501 CB2 agonists; pain, neurodegenative disorders, eating disorders, weight loss or control, obesity, dyslipidemia, drug abuse; 5-(2,4-difluorophenyl)-4,5-diazatricyclo[5.2.1.0.sup.2,6.]deca-2-(6),3-dien-3-yl-phenylmethanone; |
| 08/21/2008 | US20080200500 Quinoline Derivatives as Nk3 Antagonists |
| 08/21/2008 | US20080200498 Pharmaceutical Composition For The Treatment Of Disorders Of Sexual Desire |
| 08/21/2008 | US20080200497 inhibitors of the hepatitis C virus NS3 protease; azalactone intermediate reacted with cycloalkylsulfonamide and decylization; urea or carbamate-terminated alkylglycine. hydroxyproline, cyclopropylglycine tripeptide |
| 08/21/2008 | US20080200496 SUBSTITUTED 1H-PYRROLO[3,2-b, 3,2-c, and 2,3-c]PYRIDINE-2-CARBOXAMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE Ie |
| 08/21/2008 | US20080200495 Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof |
| 08/21/2008 | US20080200494 Imidazopyridine Derivatives |
| 08/21/2008 | US20080200493 Use of Oxycodone for Treating Visceral Pain |
| 08/21/2008 | US20080200492 Methods for the treatment of alcohol abuse, addiction and dependency |
| 08/21/2008 | US20080200491 1,2-Dihydro-Spiro[3H-Indole-3,4'-Piperidine] Compounds, as Modulators of the Mas Receptor Novel |
| 08/21/2008 | US20080200490 Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidino Propanamide Compounds as Orl-1-Receptor Antagonists |
| 08/21/2008 | US20080200489 Combination of Organic Compounds |
| 08/21/2008 | US20080200488 Combination comprising at least one pyrimidylaminobenzamide compound and an HSP90 inhibitor such as 17-allylamino-17-demethoxygeldanamycin has a beneficial effect in treatment of proliferative diseases, e.g., tumors, myelomas, leukemias, psoriasis, restenosis, sclerodermitis and fibrosis |
| 08/21/2008 | US20080200487 Prepared by reacting free base with an acid in methanol under a nitrogen atmosphere; use in treating a disease which responds to an inhibition of protein kinase activity |
| 08/21/2008 | US20080200486 Combination Of Organic Compounds |
| 08/21/2008 | US20080200485 of Aurora-2 (Aurora-A) protein kinase; anticancer; 6-(pyrazolylamino)-4-pyrimidine carboxamides; Methyl 2-(4-cyclopropanecarboxamidophenylsulfanyl)-5-amino-6-(5-methylpyrazol-3-ylamino)-4-pyrimidinecarboxylate |
| 08/21/2008 | US20080200484 Pharmaceutical Compositions Comprising A Multifunctional Phosphodiesterase Inhibitor and An Adenosine Uptake Inhibitor |
| 08/21/2008 | US20080200483 Purine Derivatives for Use as Adenosin A-2A Receptor Agonists |
| 08/21/2008 | US20080200482 Use of a Partially Neutralized, Anionic (Meth)Acrylate Copolymer as a Coating for the Production of a Medicament Releasing Active Substance at Reduced Ph Values |
| 08/21/2008 | US20080200481 Method of treatment of myocardial infarction |
| 08/21/2008 | US20080200479 Acid moiety selected from pyroglutamic acid, N-(2-carboxyphenyl)-glycine acid, diglycolic acid, orotic acid, galactaric acid, nicotinic acid, hippuric acid; treatment of nervous system disorders such as schizophrenia, obsessive compulsive disorder, bipolar depression, anxiety, mania, Tourette syndrome |
| 08/21/2008 | US20080200478 1,7-Bis-(2,6,6-trimethylcyclohex-1-en-1-yl)-1 (E)-heptadiene-3,5-dione, analogs and derivatives thereof for treating cancer; potent inhibitory effect on the proliferation of human promyelocyte leukemia HL-60 cells |
| 08/21/2008 | US20080200476 Alaphatic pyrazinoylguanidine sodium channel blockers |
| 08/21/2008 | US20080200475 platelet dependent thrombosis; P2Y12 receptor antagonists; Ethyl N-[({4-[4-(1,1'-biphenyl-4-ylcarbonyl)piperazin-1-yl]-6-ethylthieno[- 2,3-d]pyrimidin-2-yl}amino)carbonyl]glycinate |
| 08/21/2008 | US20080200474 Novel flunarizine salt forms and methods of making and using the same |
| 08/21/2008 | US20080200473 GABA a receptor; hypnotic agents with a lower risk of side effects; sleep, sedative, muscle relaxant; 4-Dimethylamino-N-(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylmethyl)-benzamide |
| 08/21/2008 | US20080200472 urinary incontinence, ulcer, inflammatory bowel disease, addiction, Parkinson's, anxiety, epilepsy, seizures, pruritus, psychosis, cognitive disorder, Huntington's chorea, ALS, retinopathy, migraine, vomiting, dyskinesia, depression; Pyridazinylpiperazine compounds; VR1 Vanilloid Receptor 1 antagonists |
| 08/21/2008 | US20080200471 central nervous system disorders; mood or cognitive disorder; gastrointestinal disorders; 4-methyl-7-[(6-piperazin-1-yl-1H-indol-1-yl)sulfonyl]-3,4-dihydro-2H-1,4-benzoxazine; 1-methyl-5-[(6-piperazin-1-yl-1H-indol-1-yl)sulfonyl]-1H-indole; 6-(6-Piperazin-1-yl-indole-1-sulfonyl)-4H-benzo[1,4]oxazin-3-one |
| 08/21/2008 | US20080200470 serotonin 5-HT1A receptor agonists; N-heterocyclclediones substituted with a chroman-2-yl, 2-quinolyl, or phenoxy group; 2-[4-[(Chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydroimidazo[1,5-a]pyridine; Parkinson's, cerebral damage by thromboembolitic ictus, depression, migraine, psychosis, urinary disorde |
| 08/21/2008 | US20080200469 Phthalazinone derivatives |
| 08/21/2008 | US20080200468 2-Substituted 5-Membered Heteroaryl Carboxylates as Hm74a Receptor Agonists |
| 08/21/2008 | US20080200467 alpha keto amides and alpha hydroxy amides; N-[3-(3-Morpholin-4-yl-propoxy)-phenyl]-2-oxo-2-(4-trifluoromethyl-phenyl)-acetamide; N-Adamantan-1-yl-2-(3-benzyloxyphenyl)-2-hydroxy-acetamide; hypertensive, cardiovascular, inflammatory, pulmonary, and diabetic-related diseases |
| 08/21/2008 | US20080200466 Organic Compounds For the Treatment of Inflammatory or Allergic Conditions |
| 08/21/2008 | US20080200465 Antipathogenic benzamide compounds |
| 08/21/2008 | US20080200464 Use treating hepatocyte growth factor (HGF)-mediated diseases such as cancer; inhibitors of c-Met; e.g. 3-(3-fluoro-4-(7-methoxyquinolin-4-yloxy)phenylamino)-N-phenylpyrazine-2-carboxamide |
| 08/21/2008 | US20080200463 N-[5-(5-formyl-2-thienyl)-4-methyl-1,3-thiazol-2-yl]acetamide; autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer |
| 08/21/2008 | US20080200462 Substituted pyrazole and triazole compounds as ksp inhibitors |
| 08/21/2008 | US20080200461 Use as agricultural pesticide, fungicide, herbicide, also a pharmaceutical, for treating obesity, metabolic syndrome, atherosclerosis, cardiovascular disease and insulin resistance, diabetes, fungal infections; compounds are diamines or derivatives, with at least one tert-amine or quaternary ammonium |
| 08/21/2008 | US20080200460 Chemical Compounds |
| 08/21/2008 | US20080200459 Tetrahydroquinoline cannabinoid receptor modulators |
| 08/21/2008 | US20080200458 Inhibiting Delta 5-desaturase by contacting Delta 5-desaturase with a compound such as N-(3-chlorophenyl)thieno[3,2-d]pyrimidin-4-amineor a pharmaceutically acceptable salt or solvate thereof; treating, preventing and managing disorders e.g., obesity, diabetes |
| 08/21/2008 | US20080200456 Adenosine A2B receptor antagonists; asthma, allergies, allergic diseases or an autoimmune disease, diarrheal diseases, insulin resistance, diabetes, cancer, ischemia, reperfusion injuries, retinopathy; e.g. 1,3-Dipropyl-8-(6-chloro-3-pyridyl)xanthine |
| 08/21/2008 | US20080200455 1-Aryl- or 1-Alkylsulfonyl-Heterocyclylbenzazoles As 5-Hydroxytryptamine-6 Ligands |
| 08/21/2008 | US20080200454 Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
| 08/21/2008 | US20080200453 Administering dopamine antagonist such as bromocriptine; hypotensive agents, metabolism disorders, obesity, hypertension, hypertriglyceridemia, and insulin resistance (with or without treating obesity or endothelial dysfunction) associated with or independent from Metabolic Syndrome |
| 08/21/2008 | US20080200452 Oral, Rapidly Disintegrating Film, Which Cannot be Spat Out, for a Neuroleptic |
| 08/21/2008 | US20080200451 Antitumor agents; use in combination with other drugs such as pentamidine |
| 08/21/2008 | US20080200450 Use of ivabradine for obtaining medicaments intended for the treatment of endothelial dysfunction |
| 08/21/2008 | US20080200449 For treating pulmonary hypertension; device can provide patients with a high degree of autonomy |
| 08/21/2008 | US20080200448 New Pyridine Analogues VIII 518 |
| 08/21/2008 | US20080200447 Neurotherapeutic Compositions and Method |
| 08/21/2008 | US20080200446 1,4-Diphenyl-3-substituted azetidin-2-ones; can be metabolized in vivo to form a sterol and/or stanol absorption inhibitor and a sterol biosynthesis inhibitor for treatment of atherosclerosis, hypercholesterolemia, or sitosterolemia |
| 08/21/2008 | US20080200445 Heterocyclic aspartyl protease inhibitors |
| 08/21/2008 | US20080200444 Soluble epoxide hydrolase inhibitors |
| 08/21/2008 | US20080200443 Zinc complexes of natural amino acids for treating elevated copper caused toxicities |
| 08/21/2008 | US20080200442 Use of fluoroquinolone antibiotic such as 1-cyclopropyl-8-chloro-6-fluoro-1,4-dihydro-7-(3-aminoazepan-1-yl)-4-oxo-3-quinolinecarboxylic acid; treating antibiotic resistant infections |